Published 1 year ago

US regulator approves teplizumab which can delay the onset of Type 1 diabetes

Summary by Ground News

The world's first treatment which can delay the development of Type 1 diabetes has been licensed in the US.

0 Articles

All

Left

Center

Right

BBC News

Game-changing type 1 diabetes drug approved in US

It is the first drug to be approved that delays the onset of the condition.

1 year ago·United Kingdom

Read Full Article

CTV News

U.S. FDA approves first treatment to delay onset of type 1 diabetes

A biologic therapy that delays the onset of type 1 diabetes received approval from the U.S. Food and Drug Administration on Thursday.

1 year ago·Canada

Read Full Article

Reuters

U.S. FDA greenlights Provention Bio's diabetes drug

Provention Bio said on Thursday the U.S. Food and Drug Administration had approved the use of its drug teplizumab in those aged eight years and older, the first treatment aimed at delaying the onset of insulin-dependent type 1 diabetes.

1 year ago·United Kingdom

Read Full Article

USA Today

FDA approves first treatment that delays Type 1 diabetes. Why it could be 'game changing'

A vial of TZIELD costs nearly $14,000, a notable price given the escalating cost of lifesaving insulin for people with diabetes.

1 year ago·United States

Read Full Article

abc News

FDA approves 1st drug to delay onset of Type 1 diabetes

For the first time, the U.S. Food and Drug Administration on Thursday approved a treatment that can delay the onset of Type 1 diabetes. Teplizumab, a monoclonal antibody that will be marketed under the brand name Tzield from pharmaceutical companies ProventionBio and Sanofi, is administered through intravenous infusion. The injection was shown in clinical trials to delay onset of insulin-dependent Type 1 diabetes for patients with autoantibody

1 year ago·United States

Read Full Article